Overview

Dapagliflozin for Long COVID Syndrome

Status:
NOT_YET_RECRUITING
Trial end date:
2029-06-30
Target enrollment:
Participant gender:
Summary
This is a randomized, placebo-controlled study. Patients with long COVID will be randomized to receive dapagliflozin or placebo for 12 months.
Phase:
PHASE3
Details
Lead Sponsor:
Ottawa Heart Institute Research Corporation
Treatments:
dapagliflozin